Product1 distinct publisher3 min readUpdated
A 34 percent premium still prices a company growing 17 percent at under three times sales. Independent practices should read the AI-and-payments roadmap as a pricing plan.
The Product Desk · Product desk

Compiled by The Product DeskSomething wrong?How this is made
Weave Communications agreed to be acquired by Francisco Partners for $650 million in an all-cash deal, with shareholders receiving $7.40 a share, a premium of roughly 34 percent to the August 17 close [1][2]. The premium is not the interesting number: $650 million against $239 million of fiscal 2025 revenue is about 2.7 times sales for a business that grew 17 percent [8][1].
Weave sells patient communication, scheduling and payments software to independent medical, dental, optometry and veterinary practices, a customer base its chief executive Brett White has described as one most software companies overlook [4][5]. The operating numbers are not the problem. Fiscal 2025 revenue was $239 million, up 17 percent, and first-quarter fiscal 2026 revenue was $65.5 million, also up 17 percent year over year [8][9], which annualizes to roughly $262 million and puts the deal at about 2.5 times a forward run rate [2].
The public market valuation is the problem. Weave closed at $7.28 after a 32 percent jump on the announcement, and even with that move it was down 4 percent year to date and more than 8 percent over twelve months [10][11]. Its all-time high after the November 2021 IPO was $22.40, so the take-private price is about 67 percent below the peak, and the $650 million headline is roughly 46 percent of the $1.4 billion market cap Weave once carried [11][3][6]. SiliconANGLE attributes part of that derating to investor fear of an AI-driven "SaaSpocalypse," in which cheap software generation erodes subscription businesses [16]. Note also that the $582.5 million market cap at $7.28 implies about 80 million shares, worth roughly $592 million at $7.40, so the $650 million figure includes something beyond basic equity [11][5].
What happens next is written into the stated plan. White said the deal will let Weave invest in its AI platform and deepen its payments and revenue cycle management capabilities [6], and Weave has already bought TrueLark, an AI front-desk automation startup, to extend agentic AI to multi-location practices [7]. Payments and revenue cycle work are take-rate businesses rather than seat businesses. That is the most plausible route to growing a $239 million revenue base faster than you can add independent practices, and it is a route that runs through existing customers' invoices rather than new logos.
Francisco Partners has raised more than $75 billion since 1999 and invested in over 500 technology companies, including healthcare software [12]. It bought practice management vendor AdvancedMD for $1.125 billion in November 2024, about 1.7 times what it is paying for Weave [13][7]. Co-President Ezra Perlman described Weave's position at the center of how tens of thousands of practices communicate with patients and collect revenue as "difficult to build and harder still to replicate" [14]. That is a description of switching costs, which is also the precondition for raising prices.
The board approved unanimously, and the deal still needs shareholder approval and regulatory clearance, with closing expected before the end of the year [15]. Watch for shareholder objections to a 34 percent premium struck 67 percent below the high [2][3]; watch whether Weave and AdvancedMD are packaged together [13]; and watch the first renewal cycle after close for bundled AI receptionist and payments pricing.
Follow any of these and your For You feed starts watching them — no settings page required.
Ranked by verification strength, evidence, and original report placement.
White said: "Together with Francisco Partners, we will be able to enhance our ability to invest in our AI platform, deepen our payments and revenue cycle management capabilities and further our vision for a better healthcare experience at every practice."
Weave Communications said it will exit the public markets after agreeing to be acquired for $650 million by private equity firm Francisco Partners in an all-cash deal.
Weave shareholders will receive $7.40 per share, a premium of around 34 percent to Weave's closing stock price on August 17.
Weave will delist from the New York Stock Exchange, where it has traded under the ticker WEAV since going public in 2021, when the deal closes.
Founded in 2008, Weave makes a patient communication platform for independent medical, dental, optometry and veterinary practices, used to send patient communications, schedule appointments and process payments.
According to Chief Executive Brett White, Weave's customer base is a category most software companies overlook.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Specific figures, single outlet, no primary documents
Deal terms, premium, revenue, share price and buyer history are all concretely stated and internally consistent enough to support arithmetic, but every fact traces to one trade publication with no filing, press release or second outlet. One reported figure set does not reconcile: the implied equity value is roughly $58 million below the $650 million headline with no capital structure explanation.
Real revenue-scale customer base, no unit or retention detail
Weave is an operating business at $239 million annual revenue growing 17 percent, with Q1 fiscal 2026 at $65.5 million, and the buyer describes tens of thousands of practices on the platform, which is durable adoption evidence. It is not disaggregated: no customer counts from the company, no retention, churn or AI-feature usage data, and the TrueLark agentic capability has no disclosed deployment footprint.
Deal math is sober; AI framing runs ahead of evidence
The valuation reporting is deflationary rather than promotional: under three times revenue and roughly 46 percent of peak market cap are stated plainly. The overstatement sits in the narrative layer, where the AI platform roadmap, agentic capability and the publisher's SaaSpocalypse causation are asserted without product, usage or market evidence, and the buyer's moat language is passed through unchallenged.
Both quoted voices are deal principals
Every forward-looking statement comes from a party with a direct stake in the transaction closing: the CEO of the company being sold and the co-President of the acquiring fund. No shareholder, customer, competitor or independent analyst is quoted, and the article does not test whether $7.40 is adequate value, so promotional framing is uncontested in the record.
Numbers checkable, interpretation thin
Confidence is moderate: the transaction facts and multiples are arithmetically verifiable from the disclosed figures, but the cluster has one publisher, one unreconciled valuation discrepancy, interested-party quotes as the only qualitative input, and an unevidenced causal story about AI pressure on SaaS multiples.
invest
Three South African banks lend $527M to Ghana's Genser, ahead of a $350M equity raise1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.